Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
3
75%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated1
Completed1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

terminated125%
completed125%
recruiting125%
withdrawn125%

Recent Activity

1 active trials
Showing 4 of 4
withdrawnphase_3

DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

NCT03905902
recruitingphase_2

A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

NCT04834544
completedphase_2

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

NCT03657966
terminatedphase_2

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

NCT02107378

Clinical Trials (4)

Showing 4 of 4 trials
NCT03905902Phase 3

DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Withdrawn
NCT04834544Phase 2

A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

Recruiting
NCT03657966Phase 2

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Completed
NCT02107378Phase 2

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4